High-Value Federal Grants ($5M+) — June 17, 2026

TOTE Services has already received $264.2M of the $309.6M firm-fixed-price delivery order from the Maritime Administration, reducing future payment risk and providing multi-year revenue visibility through August 2029.

The $103.3M firm-fixed-price contract for a complex wastewater treatment plant replacement in Yosemite National Park transfers full cost overrun risk to Kiewit over a 5.5-year performance period, with no options for adjustment.

Leidos Biomedical Research’s cost-plus-fixed-fee delivery order from NIH NCI runs through August 2024 with $52.2M still obligated, making the upcoming re-compete a catalyst for either contract extension or competitive displacement.

Kiewit Infrastructure West Co. bears high fixed-price execution risk on the $103.3M Yosemite wastewater treatment plant project, with full obligation at award and no options; cost overruns could pressure margins given the 5.5-year construction timeline.

TOTE Services’ $309.6M contract represents a single-vessel delivery order with no follow-on options, concentrating revenue risk on one program; any delay or cost overrun could materially impact the company’s shipbuilding backlog.

Leidos’ $126.4M NIH contract expires August 2024 with no options, exposing the revenue stream to NIH NCI budget appropriations and potential re-compete outcomes; NIH funding for GOCO facilities is stable but not guaranteed beyond FY2024.

TOTE Services’ NSMV V award positions it for follow-on vessel construction contracts from the Maritime Administration, as the program supports a fleet of training ships; the 85% outlayed funding signals strong government commitment.

Although only one-third of aggregate value is defense-related, the NSMV V contract supports DOD maritime training needs; investors should watch for defense budget increases tied to shipbuilding in the FY2027 NDAA.

Kiewit’s Yosemite wastewater treatment plant contract may lead to additional National Park Service infrastructure awards, supported by the full obligation of funds at award—a positive signal for federal civilian construction spending.

The $413 million combined civilian awards (TOTE’s shipbuilding and Kiewit’s NPS project) demonstrate continued federal commitment to non-defense infrastructure, with full funding at award reducing cancellation risk despite CR uncertainty.

Leidos’ $126.4M cost-plus-fixed-fee NIH facility contract confirms steady demand for GOCO R&D operations, but the absence of options limits visibility; the re-compete in 2024 will test Leidos’ competitive positioning.

{"entity"=>"TOTE SERVICES, LLC", "reason"=>"85% pre-funded $309.6M NSMV V contract with firm-fixed-price execution risk through August 2029; key maritime training asset for DOD.", "trigger"=>"NSMV V construction milestones; DOD FY2027 shipbuilding budget; Maritime Administration follow-on solicitations"}

{"entity"=>"Leidos Holdings, Inc.", "reason"=>"$126.4M NIH contract expires August 2024 with $52.2M remaining; re-compete outcome will impact federal R&D services backlog.", "trigger"=>"NIH NCI re-compete solicitation release; FY2024 appropriations; contract extension announcement"}

{"entity"=>"Kiewit Infrastructure West Co.", "reason"=>"$103.3M Yosemite wastewater plant is fixed-price with high execution risk; materiality to parent is low but cost overruns could signal broader project management issues.", "trigger"=>"Quarterly earnings cost disclosures; NPS infrastructure budget updates; subcontractor awards"}